Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAS825 in XIAP Deficiency
NCT06309823Phase 3Completed
- Sponsor
- SickKids
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of MAS825 in X-linked lymphoproliferative syndrome type 2 (XLP2), sponsored by SickKids. Started Feb 2023; status: completed.
02
Drugs
MAS825
03
Conditions
X-linked lymphoproliferative syndrome type 2 (XLP2)
Beyond the preview
Go deeper on NCT06309823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06309823.